vs

Side-by-side financial comparison of Falcon's Beyond Global, Inc. (FBYD) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

SUTRO BIOPHARMA, INC. is the larger business by last-quarter revenue ($11.6M vs $6.6M, roughly 1.8× Falcon's Beyond Global, Inc.). On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs -21.4%). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs -5.4%).

500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

FBYD vs STRO — Head-to-Head

Bigger by revenue
STRO
STRO
1.8× larger
STRO
$11.6M
$6.6M
FBYD
Growing faster (revenue YoY)
FBYD
FBYD
+404.8% gap
FBYD
383.5%
-21.4%
STRO
Faster 2-yr revenue CAGR
FBYD
FBYD
Annualised
FBYD
108.4%
-5.4%
STRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FBYD
FBYD
STRO
STRO
Revenue
$6.6M
$11.6M
Net Profit
$-296.0K
Gross Margin
Operating Margin
-30.9%
Net Margin
-4.5%
Revenue YoY
383.5%
-21.4%
Net Profit YoY
97.5%
35.4%
EPS (diluted)
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBYD
FBYD
STRO
STRO
Q4 25
$6.6M
$11.6M
Q3 25
$4.1M
$9.7M
Q2 25
$2.5M
$63.7M
Q1 25
$1.7M
$17.4M
Q4 24
$1.4M
$14.8M
Q3 24
$2.1M
$8.5M
Q2 24
$1.8M
$25.7M
Q1 24
$1.5M
$13.0M
Net Profit
FBYD
FBYD
STRO
STRO
Q4 25
$-296.0K
Q3 25
$-10.4M
$-56.9M
Q2 25
$25.1M
$-11.5M
Q1 25
$-8.1M
$-76.0M
Q4 24
$-11.9M
$-72.4M
Q3 24
$39.3M
$-48.8M
Q2 24
$8.0M
$-48.0M
Q1 24
$114.0M
$-58.2M
Operating Margin
FBYD
FBYD
STRO
STRO
Q4 25
-30.9%
Q3 25
-90.9%
-499.9%
Q2 25
-53.0%
-5.2%
Q1 25
-371.1%
-393.8%
Q4 24
-335.6%
-440.7%
Q3 24
-118.9%
-797.2%
Q2 24
-195.9%
-189.4%
Q1 24
-350.5%
-435.0%
Net Margin
FBYD
FBYD
STRO
STRO
Q4 25
-4.5%
Q3 25
-256.8%
-586.6%
Q2 25
985.2%
-18.0%
Q1 25
-473.8%
-436.6%
Q4 24
-871.7%
-489.2%
Q3 24
1899.5%
-572.6%
Q2 24
446.5%
-186.8%
Q1 24
7521.4%
-447.5%
EPS (diluted)
FBYD
FBYD
STRO
STRO
Q4 25
$-0.01
Q3 25
$-0.13
$-0.67
Q2 25
$0.30
$-0.14
Q1 25
$-0.13
$-0.91
Q4 24
$-0.25
$-27.63
Q3 24
$0.39
$-0.59
Q2 24
$0.00
$-0.59
Q1 24
$1.27
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBYD
FBYD
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$1.9M
$141.4M
Total DebtLower is stronger
$15.6M
Stockholders' EquityBook value
$11.9M
$-132.5M
Total Assets
$66.7M
$173.8M
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBYD
FBYD
STRO
STRO
Q4 25
$1.9M
$141.4M
Q3 25
$4.3M
$167.6M
Q2 25
$26.1M
$205.1M
Q1 25
$1.1M
$249.0M
Q4 24
$825.0K
$316.9M
Q3 24
$828.0K
$388.3M
Q2 24
$1.7M
$375.6M
Q1 24
$1.1M
$267.6M
Total Debt
FBYD
FBYD
STRO
STRO
Q4 25
$15.6M
Q3 25
Q2 25
Q1 25
Q4 24
$41.2M
Q3 24
$10.3M
Q2 24
$15.7M
Q1 24
$15.1M
Stockholders' Equity
FBYD
FBYD
STRO
STRO
Q4 25
$11.9M
$-132.5M
Q3 25
$9.2M
$-87.3M
Q2 25
$414.0K
$-32.1M
Q1 25
$-11.6M
$-25.8M
Q4 24
$-9.0M
$44.6M
Q3 24
$-1.4M
$111.2M
Q2 24
$-44.7M
$152.2M
Q1 24
$-61.7M
$98.0M
Total Assets
FBYD
FBYD
STRO
STRO
Q4 25
$66.7M
$173.8M
Q3 25
$66.8M
$209.7M
Q2 25
$89.2M
$262.4M
Q1 25
$56.7M
$321.4M
Q4 24
$61.2M
$387.2M
Q3 24
$66.5M
$451.8M
Q2 24
$65.9M
$489.0M
Q1 24
$67.8M
$403.4M
Debt / Equity
FBYD
FBYD
STRO
STRO
Q4 25
1.31×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBYD
FBYD
STRO
STRO
Operating Cash FlowLast quarter
$-4.3M
$-177.2M
Free Cash FlowOCF − Capex
$-4.3M
FCF MarginFCF / Revenue
-66.0%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBYD
FBYD
STRO
STRO
Q4 25
$-4.3M
$-177.2M
Q3 25
$-13.3M
$-38.2M
Q2 25
$-7.9M
$-44.7M
Q1 25
$945.0K
$-67.9M
Q4 24
$-3.8M
$-71.7M
Q3 24
$-2.4M
$-64.5M
Q2 24
$-2.6M
$9.5M
Q1 24
$-3.8M
$-64.7M
Free Cash Flow
FBYD
FBYD
STRO
STRO
Q4 25
$-4.3M
Q3 25
$-13.4M
Q2 25
Q1 25
$853.0K
Q4 24
$-3.8M
Q3 24
$-2.4M
Q2 24
$-2.6M
Q1 24
$-3.8M
FCF Margin
FBYD
FBYD
STRO
STRO
Q4 25
-66.0%
Q3 25
-329.6%
Q2 25
Q1 25
49.9%
Q4 24
-278.7%
Q3 24
-114.9%
Q2 24
-145.6%
Q1 24
-248.8%
Capex Intensity
FBYD
FBYD
STRO
STRO
Q4 25
0.3%
Q3 25
1.0%
Q2 25
0.0%
Q1 25
5.4%
Q4 24
0.1%
Q3 24
0.2%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
FBYD
FBYD
STRO
STRO
Q4 25
Q3 25
Q2 25
-0.31×
Q1 25
Q4 24
Q3 24
-0.06×
Q2 24
-0.33×
Q1 24
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons